Q3 2025: Solid Organic Growth Across All Sectors

Strong performance by Process Solutions, Rare Diseases and Semiconductor Solutions.

KEY FACTS AND FORECAST

Financial results for Q3 2025

  • Net sales increase organically by +5.2% to € 5.3 billion; foreign exchange effects of –4.9%, portfolio effects of +0.7%
  • EBITDA pre grows organically by +8.8% to € 1.7 billion; foreign exchange effects of –6.5%, portfolio effects of +0.9%
  • Strong performance by Process Solutions, Rare Diseases and Semiconductor Solutions

Guidance for 2025

  • Company confirms guidance for 2025

Overview: business performance in Q3 2025

 

Q3 2025

(in € billion)

Total change

(in %, compared to Q3 2024)

Organic change

(in %, compared to Q3 2024)

Group net sales

5.3

1.0

5.2

EBITDA pre

1.7

3.1

8.8

Life Science sales

2.2

1.4

5.9

Healthcare sales

2.2

3.2

4.6

Electronics sales

0.9

–5.2

4.8

Belén Garijo - Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany Belén Garijo - Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany

”We delivered solid organic growth across all three business sectors, illustrating the resilience of our diversified portfolio against significant external headwinds.”

Belén Garijo

Chair of the Executive Board and CEO of Merck KGaA, Darmstadt, Germany

Conference calls for the media and analysts

  • Conference call for the media
    The conference call for the media will take place at 9:30 a.m. (CET)

  • Conference call for analysts
    The conference call for analysts can be followed live via webcast at 2 p.m. (CET)

Related News

View All News
  1. Press Releases

    Q3 2025: Solid Organic Growth Across All Sectors

    Strong performance by Process Solutions, Rare Diseases and Semiconductor Solutions.

    2025/11/13

Upcoming Events

View All Events

Timo Breiner

Media Relations

Florian Schraeder

Head of Investor Relations

+49 6151 72 5271

+49 6151 72 91-5271

Share Price

Our interactive Share Price Tool provides you with all the information you need. You can retrace our development within the last ten years or follow it in real time – or compare our share price to various indices.

Check Share Price